Literature DB >> 19898788

[Anticoagulation in critically ill patient].

Dietmar Fries1.   

Abstract

Incidence of deep vein thrombosis in critically ill patients depends on the underlying disease but may be as high as 60%. In patients with severe sepsis or septic shock, Surviving Sepsis Campaign clearly recommends administering anticoagulation in the absence of specific contraindications. The article discusses risk factor for thromboembolic events in critical illness, non-pharmacological and pharmacological thrombosis prophylaxis as well as means of monitoring anticoagulation. Considering the ideal route of administration in intensive care patients, peripheral vasoconstriction, edema, shock, and administration of catecholamines may reduce bioavailability and efficacy of subcutaneous administration of low molecular weight heparin (LMWH). Dosing of the direct thrombin inhibitor argatroban depends on the severity of illness (SAPS II-score) and is up to 10-times lower than in patients without critical illness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19898788     DOI: 10.1007/s10354-009-0713-5

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  20 in total

1.  Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors.

Authors:  Deborah Cook; Mark Crowther; Maureen Meade; Christian Rabbat; Lauren Griffith; David Schiff; William Geerts; Gordon Guyatt
Journal:  Crit Care Med       Date:  2005-07       Impact factor: 7.598

2.  Screening for asymptomatic deep vein thrombosis in surgical intensive care patients.

Authors:  L M Harris; G R Curl; F V Booth; J M Hassett; G Leney; J J Ricotta
Journal:  J Vasc Surg       Date:  1997-11       Impact factor: 4.268

3.  A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma.

Authors:  W H Geerts; R M Jay; K I Code; E Chen; J P Szalai; E A Saibil; P A Hamilton
Journal:  N Engl J Med       Date:  1996-09-05       Impact factor: 91.245

4.  Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin.

Authors:  A J Mayr; M Dünser; S Jochberger; D Fries; A Klingler; M Joannidis; W Hasibeder; Wolfgang Schobersberger
Journal:  Thromb Res       Date:  2002-02-01       Impact factor: 3.944

5.  Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin.

Authors:  D Green; M Y Lee; A C Lim; J S Chmiel; M Vetter; T Pang; D Chen; L Fenton; G M Yarkony; P R Meyer
Journal:  Ann Intern Med       Date:  1990-10-15       Impact factor: 25.391

6.  A prospective study of venous thromboembolism after major trauma.

Authors:  W H Geerts; K I Code; R M Jay; E Chen; J P Szalai
Journal:  N Engl J Med       Date:  1994-12-15       Impact factor: 91.245

7.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

8.  Deep venous thrombosis and pulmonary embolism. Frequency in a respiratory intensive care unit.

Authors:  K M Moser; J R LeMoine; F J Nachtwey; R G Spragg
Journal:  JAMA       Date:  1981-09-25       Impact factor: 56.272

Review 9.  Venous thromboembolism and its prevention in critical care.

Authors:  William Geerts; Deborah Cook; Rita Selby; Edward Etchells
Journal:  J Crit Care       Date:  2002-06       Impact factor: 3.425

10.  Argatroban anticoagulation in critically ill patients.

Authors:  Martin Beiderlinden; Tanja A Treschan; Klaus Görlinger; Jürgen Peters
Journal:  Ann Pharmacother       Date:  2007-04-17       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.